A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?
J Cardiovasc Pharmacol Ther
; 24(1): 3-10, 2019 01.
Article
em En
| MEDLINE
| ID: mdl-29940780
ABSTRACT
Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and those with heart failure. This is a review of postmarket data, including real-world efficacy and safety in a variety of populations. Dofetilide has been used off-label with success in patients with paroxysmal atrial fibrillation and atrial flutter, as well as atrial tachycardia and ventricular tachycardia. The real-world acute conversion rate of atrial fibrillation and atrial flutter is higher than that reported in clinical trials. Dofetilide has an acceptable safety profile when initiated (or reloaded) under hospital monitoring and dosed according to creatinine clearance. Dofetilide is well tolerated and a good choice for patients with acceptable renal function and a normal QT interval, especially if atrioventricular nodal blockade needs to be avoided.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Fenetilaminas
/
Fibrilação Atrial
/
Flutter Atrial
/
Sulfonamidas
/
Bloqueadores dos Canais de Potássio
/
Sistema de Condução Cardíaco
/
Frequência Cardíaca
/
Antiarrítmicos
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
J Cardiovasc Pharmacol Ther
Ano de publicação:
2019
Tipo de documento:
Article